Signaling pathways, microenvironment, and targeted treatments in Langerhans cell histiocytosis

被引：9
作者：
Gao, Xue-min [1 ,2 ]
Li, Jian [1 ,2 ]
Cao, Xin-xin [1 ,2 ]
机构：
[1] Peking Union Med Coll Hosp, Chinese Acad Med Sci, Peking Union Med Coll, Dept Hematol, Beijing, Peoples R China
[2] Peking Union Med Coll Hosp, Chinese Acad Med Sci, Peking Union Med Coll, State Key Lab Complex Severe & Rare Dis, Beijing, Peoples R China
来源：
CELL COMMUNICATION AND SIGNALING | 2022年 / 20卷 / 01期
基金：
北京市自然科学基金;
关键词：
Langerhans cell histiocytosis (LCH); MAPK pathway; Inflammatory myeloid malignancy; Progenitor cells; RAF inhibitors; MEK inhibitors; ERDHEIM-CHESTER DISEASE; DENDRITIC CELL; T-CELLS; ABUNDANT EXPRESSION; HIGH PREVALENCE; BRAF MUTATIONS; VEMURAFENIB; LCH; INHIBITION; MAP2K1;
D O I：
10.1186/s12964-022-00917-0
中图分类号：
Q2 [细胞生物学];
学科分类号：
071009 ; 090102 ;
摘要：
Langerhans cell histiocytosis (LCH) is an inflammatory myeloid malignancy in the "L-group " histiocytosis. Mitogen-activated protein kinase (MAPK) pathway activating mutations are detectable in nearly all LCH lesions. However, the pathogenic roles of MAPK pathway activation in the development of histiocytosis are still elusive. This review will summarize research concerning the landscape and pathogenic roles of MAPK pathway mutations and related treatment opportunities in Langerhans cell histiocytosis.
引用
收藏
页数：16
相关论文
共 121 条
  • [1] Sustained, complete response to pexidartinib in a patient with CSF1R-mutated Erdheim-Chester disease
    Abeykoon, Jithma P.
    Lasho, Terra L.
    Dasari, Surendra
    Rech, Karen L.
    Ranatunga, Wasantha K.
    Manske, Michelle K.
    Tischer, Alexander
    Ravindran, Aishwarya
    Young, Jason R.
    Tobin, William Oliver
    Flanagan, Eoin P.
    Nowakowski, Kevin E.
    Ruan, Gordon J.
    Shah, Mithun, V
    Bennani, Nabila Nora
    Vassallo, Robert
    Ryu, Jay H.
    Koster, Matthew J.
    Davidge-Pitts, Caroline J.
    Patnaik, Mrinal M.
    Wu, Xiaosheng
    Witzig, Thomas E.
    Goyal, Gaurav
    Go, Ronald S.
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 (03) : 293 - 302
  • [2] Langerhans-Cell Histiocytosis
    Allen, Carl E.
    Merad, Miriam
    McClain, Kenneth L.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (09) : 856 - 868
  • [3] Cell-Specific Gene Expression in Langerhans Cell Histiocytosis Lesions Reveals a Distinct Profile Compared with Epidermal Langerhans Cells
    Allen, Carl E.
    Li, Liunan
    Peters, Tricia L.
    Leung, Hon-Chiu Eastwood
    Yu, Alexander
    Man, Tsz-Kwong
    Gurusiddappa, Sivashankarappa
    Phillips, Michelle T.
    Hicks, M. John
    Gaikwad, Amos
    Merad, Miriam
    McClain, Kenneth L.
    [J]. JOURNAL OF IMMUNOLOGY, 2010, 184 (08) : 4557 - 4567
  • [4] Angeli Veronique, 2006, Lymphatic Research and Biology, V4, P217, DOI 10.1089/lrb.2006.4406
  • [5] Aberrant chemokine receptor expression and chemokine production by Langerhans cells underlies the pathogenesis of Langerhans cell histiocytosis
    Annels, NE
    da Costa, CET
    Prins, FA
    Willemze, A
    Hogendoorn, PCW
    Egeler, RM
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2003, 197 (10) : 1385 - 1390
  • [6] A phase IIa study of afuresertib, an oral pan-AKT inhibitor, in patients with Langerhans cell histiocytosis
    Arceci, Robert J.
    Allen, Carl E.
    Dunkel, Ira J.
    Jacobsen, Eric
    Whitlock, James
    Vassallo, Robert
    Morris, Shannon R.
    Portnoy, Alison
    Reedy, Beth Ann
    Smith, Deborah A.
    Noble, Robert
    Murnane, Amy
    Cornfeld, Mark
    Rodriguez-Galindo, Carlos
    Heaney, Mark L.
    McClain, Kenneth
    Vaiselbuh, Sarah
    [J]. PEDIATRIC BLOOD & CANCER, 2017, 64 (05)
  • [7] Targeted therapies in 54 patients with Erdheim-Chester disease, including follow-up after interruption (the LOVE study)
    Aubart, Fleur Cohen
    Emile, Jean-Francois
    Carrat, Fabrice
    Charlotte, Frederic
    Benameur, Neila
    Donadieu, Jean
    Maksud, Philippe
    Idbaih, Ahmed
    Barete, Stephane
    Hoang-Xuan, Khe
    Amoura, Zahir
    Haroche, Julien
    [J]. BLOOD, 2017, 130 (11) : 1377 - 1380
  • [8] Efficacy of the MEK inhibitor cobimetinib for wild-type BRAF Erdheim-Chester disease
    Aubart, Fleur Cohen
    Emile, Jean-Francois
    Maksud, Philippe
    Galanaud, Damien
    Cluzel, Philippe
    Benameur, Neila
    Aumaitre, Olivier
    Amoura, Zahir
    Haroche, Julien
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2018, 180 (01) : 150 - 153
  • [9] Clinical resistance associated with a novel MAP2K1 mutation in a patient with Langerhans cell histiocytosis
    Azorsa, David O.
    Lee, David W.
    Wai, Daniel H.
    Bista, Ranjan
    Patel, Apurvi R.
    Aleem, Eiman
    Henry, Michael M.
    Arceci, Robert J.
    [J]. PEDIATRIC BLOOD & CANCER, 2018, 65 (09)
  • [10] Recurrent BRAF mutations in Langerhans cell histiocytosis
    Badalian-Very, Gayane
    Vergilio, Jo-Anne
    Degar, Barbara A.
    MacConaill, Laura E.
    Brandner, Barbara
    Calicchio, Monica L.
    Kuo, Frank C.
    Ligon, Azra H.
    Stevenson, Kristen E.
    Kehoe, Sarah M.
    Garraway, Levi A.
    Hahn, William C.
    Meyerson, Matthew
    Fleming, Mark D.
    Rollins, Barrett J.
    [J]. BLOOD, 2010, 116 (11) : 1919 - 1923
12345678910